Category: Cidara Therapeutics

  • Cidara and Mundipharma prep filings for antifungal rezafungin

    Mundipharma and Cidara Therapeutics have reported the results of a phase 3 trial of their new once-weekly antifungal rezafungin, setting up regulatory filings in the coming months. The two partners say the ReSTORE trial of rezafungin, a drug in the echinocandin class, met its objectives in showing that rezafungin was as effective as daily dosing […]